Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.1612 | 0.2852 | 0.5 |
Schistosoma mansoni | 6-phosphofructokinase | 0.2731 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.1612 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.2685 | 0.9706 | 0.9706 |
Giardia lamblia | Hypothetical protein | 0.1612 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2731 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.2685 | 0.9706 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.2731 | 1 | 1 |
Onchocerca volvulus | 0.2731 | 1 | 0.5 | |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2731 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.2685 | 0.9706 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2685 | 0.9706 | 0.9706 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2731 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.2685 | 0.9706 | 0.9604 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.2731 | 1 | 0.5 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.1612 | 0.2852 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.1612 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2731 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (ADMET) | = 284 uM | Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay | ChEMBL. | 24125880 |
IC50 (functional) | = 77.87 uM | Antipromastigote activity against Leishmania braziliensis MCAN/BR/98/R619 after 24 hrs by MTT assay | ChEMBL. | 24125880 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.